Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,178,717 papers from all fields of science
Search
Sign In
Create Free Account
BL 3459
Known as:
BL-3459
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
1981
1981
Comparison of sulfinpyrazone and BL-3459 with S - 20344, a potent new antithrombotic agent.
R. L. Vigdahl
,
R. H. Ferber
,
S. Parrish
Thrombosis Research
1981
Corpus ID: 40178481
1979
1979
Evaluation of antiinflammatory and antithrombotic drugs in pulmonary and arterial thrombosis.
R. L. Vigdahl
,
R. H. Ferber
,
S. Parrish
Thrombosis Research
1979
Corpus ID: 2464924
1979
1979
Antiplatelet drugs and the generalized Shwartzman reaction in the pregnant rat.
J. Latour
,
C. Groulx
Journal of Pharmacology and Experimental…
1979
Corpus ID: 32345111
Several antiplatelet drugs (aspirin, sulfinpyrazone, hydroxychloroquine, dipyridamole, BL-3459, pyridinolcarbamate) were assayed…
Expand
1977
1977
Enhanced platelet aggregability in dogs following myocardial infarction.
J. Fleming
,
J. Buyniski
Life Science
1977
Corpus ID: 640863
1976
1976
The effect of a potent inhibitor of platelet aggregation, BL-3459, on adrenaline-induced myocardial necrosis in beagle dogs.
J. Fleming
,
J. Buchanan
,
J. Buyniski
European Journal of Pharmacology
1976
Corpus ID: 29048891
1975
1975
Pharmacology of a potent, new antithrombotic agent, 6-methyl-1,2,3,5-tetrahydroimidazo[2, 1-b] quinazolin-2-one hydrochloride monohydrate.
J. Fleming
,
J. Buyniski
,
R. L. Cavanagh
,
M. Bierwagen
Journal of Pharmacology and Experimental…
1975
Corpus ID: 44520172
The effect of 6-methyl-1,2,3,5-tetrahydroimidazo[2,1-b] quinazolin-2-one hydrochloride monohydrate (BL-3459) on platelet function…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE